|
|
|
|
 |
 |
GlaxoSmithKline Press Releases |
 |
|
|
|
|
19th December, 2003
Neurosearch and GlaxoSmithKline form strategic R&D alliance
Neurosearch and GlaxoSmithKline form strategic R&D alliance
(19 December 2003 - London) - NeuroSearch and GlaxoSmithKline (GSK) today announced a five-year research and development alliance ...
|
17th December, 2003
GlaxoSmithKline Biologicals and Institut Pasteur enter collaboration to find a SARS vaccine
GlaxoSmithKline Biologicals and Institut Pasteur enter collaboration to find a SARS vaccine
London, UK, Philadelphia, USA and Rixensart, Belgium: December 17th, 2003 -
GlaxoSmithKline Biologicals (GSK Bio) and the Institut Pasteur announced today that they have signed a Collaborative Research Agreement for the development of a candidate vaccine to prevent Severe Acute Respiratory Syndrome (SARS) ...
|
15th December, 2003
GlaxoSmithKline announces new executive remuneration arrangements
GlaxoSmithKline announces new executive remuneration arrangements
London, December 15, 2003 -
Link between pay and performance strengthened - robust EPS and TSR hurdles
Contracts for Executive Directors reduced from 24 months to 12 months without compensation
Remuneration aligned with other global pharmaceutical companies - to recruit, retain and motivate key executive talent
New policy closely aligned with UK shareholder best-practice guidelines
The Board of GlaxoSmithKline plc today announces new executive remuneration arrangements, which will cover both its Executive Directors and the company's top executive team ...
|
15th December, 2003
GlaxoSmithKline plc announces changes to the Board and its committees
GlaxoSmithKline plc announces changes to the Board and its committees
London, December 15, 2003
Appointment of new Executive Director
GSK announces that Dr Tadataka (Tachi) Yamada, Chairman, Pharmaceuticals Research & Development, has been appointed an Executive Director of GlaxoSmithKline plc with effect from 1st January 2004 ...
|
10th December, 2003
Nelarabine is active in aggressive, treatment-resistant forms of childhood T-cell leukaemia
Nelarabine is active in aggressive, treatment-resistant forms of childhood T-cell leukaemia
London & Philadelphia, December 10, 2003 - According to results of a Phase II study presented at the 45th annual meeting of the American Society of Hematology (ASH), Nelarabine (506U78) has activity as a single agent in children with T-cell malignancies that have relapsed or are refractory to prior therapy [ASH Abstract 792] ...
|
8th December, 2003
Studies presented at ASH explore activity of the Bexxar ® therapeutic regimen in difficult-to-treat lymphomas
Studies presented at ASH explore activity of the Bexxar® therapeutic regimen in difficult-to-treat lymphomas
San Diego, California, December 8, 2003 - According to several studies presented at the 45th annual meeting of the American Society of Hematology (ASH), Bexxar® (Tositumomab and Iodine I 131 Tositumomab) is active in a variety of patients with difficult-to-treat lymphomas, including patients with heavily pre-treated follicular non-Hodgkin's lymphoma who have had multiple relapses, patients who initially responded to but subsequently relapsed following the Bexxar therapeutic regimen, and patients with previously untreated mantle cell lymphoma who received Bexxar as a component of sequential therapy ...
|
6th December, 2003
Data from breast cancer study indicate early promise for GlaxoSmithKline's investigational compound GW572016
Data from breast cancer study indicate early promise for GlaxoSmithKline's investigational compound GW572016
London, San Antonio, Texas, December 6, 2003 - Data from an early phase, multi-center clinical trial suggest that GW572016, a reversible inhibitor of two growth factor receptors involved in the proliferation and survival of many solid tumors, in a once-daily oral dose has clinical and biological activity in patients with metastatic breast cancer who have received multiple prior therapies ...
|
5th December, 2003
GlaxoSmithKline donates $1.6 million to African AIDS clinics
GlaxoSmithKline donates $1.6 million to African AIDS clinics
London and Philadelphia, December 5, 2003 - As part of its long-standing commitment to care and community support for HIV/AIDS patients and developing world health initiatives, GlaxoSmithKline has announced a $1.6 million grant over two years to support the work of two HIV/AIDS clinics in Malawi and Uganda ...
|
3rd December, 2003
GlaxoSmithKline unveils a broad R&D pipeline of innovative science and class-leading compounds
GlaxoSmithKline unveils a broad R&D pipeline of innovative science and class-leading compounds
London, December 3, 2003 - At a presentation to investors today, GlaxoSmithKline demonstrated that the company’s unique R&D structure is delivering a large and diverse pipeline ...
|
1st December, 2003
Emory University, GlaxoSmithKline, and National Institute of Mental Health create partnership to develop new treatments for depression
Emory University, GlaxoSmithKline, and National Institute of Mental Health create partnership to develop new treatments for depression
London, UK and Atlanta, US, December, 1, 2003 - Through a unique partnership among academia, industry, and government, a team of scientists from Emory University School of Medicine, GlaxoSmithKline (GSK), and the National Institute of Mental Health (NIMH) will work together to accelerate the development of drugs to treat depression and other mood disorders ...
|
|
|
|
Next 10 » |
|
|
|
|
